0
Il n'y a pas de produit dans le panier !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Accueil > PVRIG

PVRIG

Brief Information

Name:Transmembrane protein PVRIG
Target Synonym:PVRIG,PVR Related Immunoglobulin Domain Containing,CD112 Receptor,Poliovirus Receptor-Related Immunoglobulin Domain-Containing Protein,Poliovirus Receptor Related Immunoglobulin Domain Containing,Nectin-2 Receptor,C7orf15,CD112R,Transmembrane Protein PVRIG,MGC2463
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:7
Lastest Research Phase:Phase 2 Clinical

Product ListCompare or Buy

Cat . Non Espèces Description du produit Structure Pureté Caractéristique
PVG-C52H3 Cynomolgus Cynomolgus PVRIG Protein, His Tag (MALS verified)
PVG-C52H3-structure
PVG-C52H3-sds
PVG-M82F3 Mouse Biotinylated Mouse PVRIG Protein, Fc,Avitag™ (MALS verified)
PVG-M82F3-structure
PVG-M82F3-sds
PVG-M82E3 Mouse Biotinylated Mouse PVRIG Protein, His,Avitag™
PVG-M82E3-structure
PVG-M82E3-sds
PVG-R52H8 Rat Rat PVRIG Protein, His Tag (MALS verified)
PVG-R52H8-structure
PVG-R52H8-sds
PVG-M52H7 Mouse Mouse PVRIG Protein, His Tag (MALS verified)
PVG-M52H7-structure
PVG-M52H7-sds
PVG-H82F4 Human Biotinylated Human PVRIG Protein, Fc,Avitag™ (MALS verified)
PVG-H82F4-structure
PVG-H82F4-sds
PVG-M5253 Mouse Mouse PVRIG Protein, Mouse IgG2a Fc Tag (MALS verified)
PVG-M5253-structure
PVG-M5253-sds
PVG-C5253 Cynomolgus Cynomolgus PVRIG Protein, Mouse IgG2a Fc Tag (MALS verified)
PVG-C5253-structure
PVG-C5253-sds
PVG-H82F5 Human Biotinylated Human PVRIG Protein, Mouse IgG2a Fc,Avitag™ (MALS verified)
PVG-H82F5-structure
PVG-H82F5-sds
PVG-H52H5 Human Human PVRIG Protein, His Tag (MALS verified)
PVG-H52H5-structure
PVG-H52H5-sds
PVG-H5259 Human Human PVRIG Protein, Mouse IgG2a Fc Tag (MALS verified)
PVG-H5259-structure
PVG-H5259-sds
PVG-H82F9 Human Biotinylated Human PVRIG Protein, Fc,Avitag™ (HPLC verified)
PVG-H82F9-structure
PVG-H82F9-sds
PVG-H82F9-hplc
PVG-H82E3 Human Biotinylated Human PVRIG Protein, His,Avitag™
PVG-H82E3-structure
PVG-H82E3-sds
PVG-H5257 Human Human PVRIG Protein, Fc Tag (MALS verified)
PVG-H5257-structure
PVG-H5257-sds
PVG-C5259 Cynomolgus Cynomolgus PVRIG Protein, Fc Tag (MALS verified)
PVG-C5259-structure
PVG-C5259-sds
PVG-M5257 Mouse Mouse PVRIG Protein, Fc Tag (MALS verified)
PVG-M5257-structure
PVG-M5257-sds
PVG-H52H4 Human Human PVRIG Protein, His Tag
PVG-H52H4-structure
PVG-H52H4-sds
ACRO Quality

Part of Bioactivity data

PVG-H5259-BLI
 PVRIG BLI

Loaded Human PVRIG, Mouse IgG2a Fc Tag (Cat. No. PVG-H5259) on Protein A Biosensor, can bind Human Nectin-2, His Tag (Cat. No. PV2-H52E2) with an affinity constant of 1 μM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

PVG-C5259-BLI
 PVRIG BLI

Loaded Cynomolgus PVRIG, Fc Tag (Cat. No. PVG-C5259) on Protein A Biosensor, can bind Human Nectin-2, His Tag (Cat. No. PV2-H52E2) with an affinity constant of 0.44 μM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

Synonym Name

C7orf15,C7orf15MGC138295,CD112R,MGC104322,MGC138297,MGC2463,PVRIG,CD112 receptor

Background

Human PVRIG (poliovirus receptor related immunoglobulin domain-containing protein), also known as CD112 receptor (CD112R), is an approximately 34 kDa single transmembrane protein in the poliovirus receptor-like protein (PVR) family. The CD112R gene encodes a putative single transmembrane protein, which is composed of a single extracellular IgV domain, one transmembrane domain, and a long intracellular domain. Notably, the intracellular domain of phatases. The extracellular domain sequence of human and mouse CD112R have 65.3% similarity. CD112R may act as a coinhibitory receptor that suppresses T-cell receptor-mediated signals.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
COM-701 COM-701 Phase 2 Clinical Compugen Ltd Ovarian Neoplasms; Head and Neck Neoplasms; Solid tumours; Small Cell Lung Carcinoma; Triple Negative Breast Neoplasms; Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Endometrial Neoplasms; Lung Neoplasms Details
SIM-0348 SIM-0348 Phase 1 Clinical Simcere Pharmaceutical Group Ltd Solid tumours; Neoplasms Details
GSK-4381562 SRF-813; GSK-4381562 Phase 1 Clinical Surface Oncology Inc Neoplasms Details
NM1F NM1F; TGI-2 Phase 1 Clinical Hefei TG ImmunoPharma Co Ltd Solid tumours; Ovarian Neoplasms; Triple Negative Breast Neoplasms; Colorectal Neoplasms; Melanoma Details
SHR-2002 SHR-2002 Phase 1 Clinical Suzhou Suncadia Biopharmaceuticals Co Ltd, Shanghai Hengrui Pharmaceutical Co Ltd Neoplasms Details
JS-009 JS009; TAB009; JS-009 Phase 1 Clinical Shanghai Junshi Biosciences Co Ltd Solid tumours; Neoplasms Details
PM-1009 PM1009 Phase 1 Clinical Biotheus Inc Solid tumours; Neoplasms; Lung Neoplasms Details
COM-701 COM-701 Phase 2 Clinical Compugen Ltd Ovarian Neoplasms; Head and Neck Neoplasms; Solid tumours; Small Cell Lung Carcinoma; Triple Negative Breast Neoplasms; Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Endometrial Neoplasms; Lung Neoplasms Details
SIM-0348 SIM-0348 Phase 1 Clinical Simcere Pharmaceutical Group Ltd Solid tumours; Neoplasms Details
GSK-4381562 SRF-813; GSK-4381562 Phase 1 Clinical Surface Oncology Inc Neoplasms Details
NM1F NM1F; TGI-2 Phase 1 Clinical Hefei TG ImmunoPharma Co Ltd Solid tumours; Ovarian Neoplasms; Triple Negative Breast Neoplasms; Colorectal Neoplasms; Melanoma Details
SHR-2002 SHR-2002 Phase 1 Clinical Suzhou Suncadia Biopharmaceuticals Co Ltd, Shanghai Hengrui Pharmaceutical Co Ltd Neoplasms Details
JS-009 JS009; TAB009; JS-009 Phase 1 Clinical Shanghai Junshi Biosciences Co Ltd Solid tumours; Neoplasms Details
PM-1009 PM1009 Phase 1 Clinical Biotheus Inc Solid tumours; Neoplasms; Lung Neoplasms Details
COM-701 COM-701 Phase 2 Clinical Compugen Ltd Ovarian Neoplasms; Head and Neck Neoplasms; Solid tumours; Small Cell Lung Carcinoma; Triple Negative Breast Neoplasms; Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Endometrial Neoplasms; Lung Neoplasms Details
SIM-0348 SIM-0348 Phase 1 Clinical Simcere Pharmaceutical Group Ltd Solid tumours; Neoplasms Details
GSK-4381562 SRF-813; GSK-4381562 Phase 1 Clinical Surface Oncology Inc Neoplasms Details
NM1F NM1F; TGI-2 Phase 1 Clinical Hefei TG ImmunoPharma Co Ltd Solid tumours; Ovarian Neoplasms; Triple Negative Breast Neoplasms; Colorectal Neoplasms; Melanoma Details
SHR-2002 SHR-2002 Phase 1 Clinical Suzhou Suncadia Biopharmaceuticals Co Ltd, Shanghai Hengrui Pharmaceutical Co Ltd Neoplasms Details
JS-009 JS009; TAB009; JS-009 Phase 1 Clinical Shanghai Junshi Biosciences Co Ltd Solid tumours; Neoplasms Details
PM-1009 PM1009 Phase 1 Clinical Biotheus Inc Solid tumours; Neoplasms; Lung Neoplasms Details
COM-701 COM-701 Phase 2 Clinical Compugen Ltd Ovarian Neoplasms; Head and Neck Neoplasms; Solid tumours; Small Cell Lung Carcinoma; Triple Negative Breast Neoplasms; Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Endometrial Neoplasms; Lung Neoplasms Details
SIM-0348 SIM-0348 Phase 1 Clinical Simcere Pharmaceutical Group Ltd Solid tumours; Neoplasms Details
GSK-4381562 SRF-813; GSK-4381562 Phase 1 Clinical Surface Oncology Inc Neoplasms Details
NM1F NM1F; TGI-2 Phase 1 Clinical Hefei TG ImmunoPharma Co Ltd Solid tumours; Ovarian Neoplasms; Triple Negative Breast Neoplasms; Colorectal Neoplasms; Melanoma Details
SHR-2002 SHR-2002 Phase 1 Clinical Suzhou Suncadia Biopharmaceuticals Co Ltd, Shanghai Hengrui Pharmaceutical Co Ltd Neoplasms Details
JS-009 JS009; TAB009; JS-009 Phase 1 Clinical Shanghai Junshi Biosciences Co Ltd Solid tumours; Neoplasms Details
PM-1009 PM1009 Phase 1 Clinical Biotheus Inc Solid tumours; Neoplasms; Lung Neoplasms Details

This web search service is supported by Google Inc.

totop

Laisser un message